公开(公告)号：EP2692728B1

公开(公告)日：2018-07-04

申请号：EP12763979.7

申请日：2012-03-30

申请人： Carna Biosciences, Inc.

发明人： IRIE Takayuki ,  SAWA Ayako ,  SAWA Masaaki ,  ASAMI Tokiko ,  FUNAKOSHI Yoko ,  TANAKA Chika

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/541 ,  A61P35/00 ,  A61P43/00 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/541 ,  C07D519/00

摘要： To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I): wherein A represents -COOR1 or a hydrogen atom; R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic fused ring, or an optionally substituted amino group; or alternatively, R2 and R3, taken together with the nitrogen atom to which they are attached, may form an optionally substituted heterocycle or an optionally substituted heterocyclic fused ring; and R4 represents a hydrogen atom or a halogen atom; with the proviso that when A represents -COOR1, R2 and R3 are not optionally substituted amino groups at the same time, and when A represents a hydrogen atom, R3 represents a hydrogen atom.

公开(公告)号：EP2692728A1

公开(公告)日：2014-02-05

申请号：EP12763979.7

申请日：2012-03-30

申请人： SBI Biotech Co., Ltd. ,  Carna Biosciences Inc.

发明人： IRIE Takayuki ,  SAWA Ayako ,  SAWA Masaaki ,  ASAMI Tokiko ,  FUNAKOSHI Yoko ,  TANAKA Chika

IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/541 ,  A61P35/00 ,  A61P43/00 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/541 ,  C07D519/00

摘要： To provide a novel furanone derivative, and a medicine including the same. The furanone derivative is represented by the formula (I):

wherein A represents -COOR1 or a hydrogen atom; R1 represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and each independently represent a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic fused ring, or an optionally substituted amino group; or alternatively, R2 and R3, taken together with the nitrogen atom to which they are attached, may form an optionally substituted heterocycle or an optionally substituted heterocyclic fused ring; and R4 represents a hydrogen atom or a halogen atom; with the proviso that when A represents -COOR1, R2 and R3 are not optionally substituted amino groups at the same time, and when A represents a hydrogen atom, R3 represents a hydrogen atom.

摘要翻译： 提供一种新的呋喃酮衍生物，以及包含它的药物。 该呋喃酮衍生物由式（I）表示：其中A表示-COOR 1或氢原子; R1代表氢原子，任选取代的烃基或任选取代的杂环; R2和R3相同或不同，各自独立地表示氢原子，任选取代的烃基，任选取代的苯基，任选取代的杂环，任选取代的杂环稠合环或任选取代的氨基; 或者可选地，R 2和R 3与它们所连接的氮原子一起可以形成任选取代的杂环或任选取代的杂环稠环; 并且R4代表氢原子或卤素原子; 条件是当A代表-COOR 1时，R 2和R 3不同时是任选取代的氨基，并且当A代表氢原子时，R 3代表氢原子。

公开(公告)号：EP3100742A1

公开(公告)日：2016-12-07

申请号：EP15743649.4

申请日：2015-01-26

申请人： Carna Biosciences, Inc.

发明人： FUNAKOSHI Yoko ,  TANAKA Chika ,  ASAMI Tokiko ,  SAWA Masaaki

IPC分类号： A61K45/06 ,  A61K31/395 ,  A61K31/444 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/553 ,  A61P35/00 ,  A61P35/02 ,  A61P43/00

CPC分类号： A61K31/553 ,  A61K31/395 ,  A61K31/437 ,  A61K31/444 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K45/06 ,  A61K2300/00

摘要： Provided is a pharmaceutical composition comprising a Cdc7 inhibitor and an M phase promoter. In particular, the Cdc7 inhibitor contained in the pharmaceutical composition is a furanone derivative represented by formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, A is -COOR1 or a hydrogen atom; R1 is a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocycle; R2 and R3 are the same or different and are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted phenyl group, an optionally substituted heterocycle, an optionally substituted heterocyclic condensed ring, or an optionally substituted amino group. Alternatively, R2 and R3 may, together with the nitrogen atoms bonding the same, form an optionally substituted heterocycle or optionally substituted heterocyclic condensed ring. R4 is a hydrogen atom or halogen atom. However, if A is -COOR1, R2 and R3 are not both simultaneously optionally substituted amino groups. When A is a hydrogen atom, R3 is a hydrogen atom.)

摘要翻译： 提供了包含Cdc7抑制剂和M相促进剂的药物组合物。 特别地，药物组合物中含有的Cdc7抑制剂是由式（I）表示的呋喃酮衍生物或其药学上可接受的盐。 （式中，A是-COOR 1或氢原子; R 1是氢原子，任选取代的烃基或任选取代的杂环; R 2和R 3相同或不同并且各自是氢原子，任选取代的 烃基，任选取代的苯基，任选取代的杂环，任选取代的杂环稠合环或任选取代的氨基，或者，R 2和R 3可以与连接它们的氮原子一起形成任选取代的杂环或 任选取代的杂环稠合环，R 4为氢原子或卤素原子，但若A为-COOR 1，则R 2和R 3不能同时为任意取代的氨基，A为氢原子时，R 3为氢原子。